Needham Reiterates Buy on Peloton Interactive, Maintains $14 Price Target
Needham analyst Bernie McTernan reiterates Peloton Interactive (NASDAQ:PTON) with a Buy and maintains $14 price target.
Why This AMD Analyst Is Bumping Up Price Target For Stock By 19% Following Q4 Results
Advanced Micro Devices Inc.
HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $19 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and maintains $19 price target.
Needham Reiterates Buy on Workday, Maintains $220 Price Target
Needham analyst Scott Berg reiterates Workday (NASDAQ:WDAY) with a Buy and maintains $220 price target.
ACM Research Likely To Gain From China’s Mature Node Investment, DRAM Spend, Analyst Says
Needham analyst Quinn Bolton maintained ACM Research Inc (NASDAQ:ACMR) with a Buy and raised the price target from $10 to $12. Bolton…
Analyst Says Selecta Biosciences’ Gout Candidate Can Potentially Raise The Bar On Several Fronts
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ:SELB) from $9 to $10 while maintaining the Buy rating ahead of…
Uber Analyst Sees Rebound In High Margin Airport Travel In Second Half, Gains From Food Delivery Business
Mizuho analyst James Lee reiterated Buy on Uber Technologies, Inc (NYSE:UBER) with a $46 price target. Based on airport and airline tracking…
Harmonic Likely To See Upside After Securing Comcast Deal And Emerges As Front-Runner For Charter Win, Analysts Say
Needham analyst Ryan Koontz reiterated Harmonic Inc (NASDAQ:HLIT) with a Buy and maintained a $19 price target. HLIT reported a strong 4Q22.…
TotalEnergies Has Minimal Underlying Exposure To Short-Seller Target Adani Group, Analyst Expects ‘Assuring Update’
In the wake of a short report targeting Adani investments last week, one analyst is diving into TotalEnergies SE's (NYSE: TTE) risk exposure<
HC Wainwright & Co. Reiterates Buy on First Wave BioPharma, Maintains $18 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates First Wave BioPharma (NASDAQ:FWBI) with a Buy and maintains $18 price target.